Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono highlights positive new study data for Erbitux

Merck Serono highlights positive new study data for Erbitux

28th April 2011

Merck Serono has highlighted a newly published study that further supports the efficacy and importance of its metastatic colorectal cancer therapy Erbitux.

An updated analysis of the phase III clinical trial Crystal has appeared in the Journal of Clinical Oncology, showing that Erbitux, combined with the chemotherapy treatment Folfiri, delivers an overall survival benefit of 3.5 months compared to Folfiri alone.

Treatment using Erbitux is dependent on the detection of certain mutations in the KRAS biomarker.

Dr Wolfgang Wein, executive vice-president for oncology at Merck Serono, noted that Crystal was the first trial to showcase the importance of this biomarker in treating the disease, leading to a shift towards personalised therapies.

"We are proud of the contribution the study has made to science and to patient care," he added.

Earlier this month, the company attended the American Academy of Neurology, where it presented positive trial data on its Parkinson's disease therapy safinamide.ADNFCR-8000103-ID-800514545-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.